Baseline morbidity in 2,990 adult African volunteers recruited to characterize laboratory reference intervals for future HIV vaccine clinical trials

Wendy Stevens, Anatoli Kamali, Etienne Karita, Omu Anzala, Eduard J Sanders, Walter Jaoko, Pontiano Kaleebu, Joseph Mulenga, Len Dally, Pat Fast, Jill Gilmour, Bashir Farah, Josephine Birungi, Peter Hughes, Olivier Manigart, Gwynn Stevens, Sarah Yates, Helen Thomson, Andrea von Lieven, Marietta Krebs, Matt A Price, Lisa Stoll-Johnson, Nzeera Ketter, Wendy Stevens, Anatoli Kamali, Etienne Karita, Omu Anzala, Eduard J Sanders, Walter Jaoko, Pontiano Kaleebu, Joseph Mulenga, Len Dally, Pat Fast, Jill Gilmour, Bashir Farah, Josephine Birungi, Peter Hughes, Olivier Manigart, Gwynn Stevens, Sarah Yates, Helen Thomson, Andrea von Lieven, Marietta Krebs, Matt A Price, Lisa Stoll-Johnson, Nzeera Ketter

Abstract

Background: An understanding of the health of potential volunteers in Africa is essential for the safe and efficient conduct of clinical trials, particularly for trials of preventive technologies such as vaccines that enroll healthy individuals. Clinical safety laboratory values used for screening, enrolment and follow-up of African clinical trial volunteers have largely been based on values derived from industrialized countries in Europe and North America. This report describes baseline morbidity during recruitment for a multi-center, African laboratory reference intervals study.

Methods: Asymptomatic persons, aged 18-60 years, were invited to participate in a cross-sectional study at seven sites (Kigali, Rwanda; Masaka and Entebbe, Uganda; Kangemi, Kenyatta National Hospital and Kilifi, Kenya; and Lusaka, Zambia). Gender equivalency was by design. Individuals who were acutely ill, pregnant, menstruating, or had significant clinical findings were not enrolled. Each volunteer provided blood for hematology, immunology, and biochemistry parameters and urine for urinalysis. Enrolled volunteers were excluded if found to be positive for HIV, syphilis or Hepatitis B and C. Laboratory assays were conducted under Good Clinical Laboratory Practices (GCLP).

Results and conclusions: Of the 2990 volunteers who were screened, 2387 (80%) were enrolled, and 2107 (71%) were included in the analysis (52% men, 48% women). Major reasons for screening out volunteers included abnormal findings on physical examination (228/603, 38%), significant medical history (76, 13%) and inability to complete the informed consent process (73, 13%). Once enrolled, principle reasons for exclusion from analysis included detection of Hepatitis B surface antigen (106/280, 38%) and antibodies against Hepatitis C (95, 34%). This is the first large scale, multi-site study conducted to the standards of GCLP to describe African laboratory reference intervals applicable to potential volunteers in clinical trials. Approximately one-third of all potential volunteers screened were not eligible for analysis; the majority were excluded for medical reasons.

Conflict of interest statement

Competing Interests: The authors have declared that no competing interests exist.

Figures

Figure 1. Map of study sites showing…
Figure 1. Map of study sites showing source populations, elevation (meters above sea level) and target enrolment.
Figure 2. Equivalent numbers of men and…
Figure 2. Equivalent numbers of men and women aged 18-60 were screened for this study.
Among the 2,990 volunteers screened, 2,387 were enrolled, and a further 263 were excluded from analysis leaving a final study cohort of 2,124 volunteers.

References

    1. UNAIDS. Report on the global AIDS epidemic. Geneva, Switzerland: Joint United Nations Program on HIV/AIDS; 2006.
    1. Fast PE, Excler J-L, Warren M, Ketter N. Clinical Site Development and Preparation for AIDS Vaccine Efficacy Trials in Developing Countries. In: Koff WC, Kahn P, Gust ID, editors. AIDS Vaccine Development - Challenges and Opportunities. Norfolk, UK: Caister Academic Press; 2007. pp. 87–98.
    1. Excler JL, Beyrer C. Human immunodeficiency virus vaccine development in developing countries: are efficacy trials feasible? J Hum Virol. 2000;3:193–214.
    1. Tsegaye A, Messele T, Tilahun T, Hailu E, Sahlu T, et al. Immunohematological reference ranges for adult Ethiopians. Clin Diagn Lab Immunol. 1999;6:410–414.
    1. Menard D, Mandeng MJ, Tothy MB, Kelembho EK, Gresenguet G, et al. Immunohematological reference ranges for adults from the Central African Republic. Clin Diagn Lab Immunol. 2003;10:443–445.
    1. Bain BJ. Ethnic and sex differences in the total and differential white cell count and platelet count. J Clin Pathol. 1996;49:664–666.
    1. Lugada ES, Mermin J, Asjo B, Kaharuza F, Downing R, et al. Immunoglobulin levels amongst persons with and without human immunodeficiency virus type 1 infection in Uganda and Norway. Scand J Immunol. 2004;59:203–208.
    1. National Committee on Clinical Laboratory Standards (NCCLS) How to define and determine reference intervals in the clinical laboratory; Approved guideline, second edition. vol 20(13) Wayne, PA, USA: NCCLS C28-A2; 2000.
    1. Glenncross D, Aggett H, Stevens W. Durban.: 2005. Results from the WHO/ NHLS/ QASI CD4 regional external quality assessment scheme (REQAS): multi-site evaluation of CD4 technology performance.
    1. Malone JL, Simms TE, Gray GC, Wagner KF, Burge JR, et al. Sources of variability in repeated T-helper lymphocyte counts from human immunodeficiency virus type 1-infected patients: total lymphocyte count fluctuations and diurnal cycle are important. J Acquir Immune Defic Syndr. 1990;3:144–151.
    1. Stiles T, Grant V, Mawbey N. Good clinical laboratory practice (GCLP): A quality system for laboratories that undertake the analysis of samples from clinical trials. Suffolk, United Kingdom: British Association of Research Quality Assurance (BARQA); 2003.
    1. Gilmour JW, Stevens W, Gray C, de Souza M. Laboratory expansion to large-scale international HIV preventative vaccine trials. Current Opinions in HIV & AIDS. 2007;2:201–206.
    1. Bland JM, Altman DG. Statistical methods for assessing agreement to large-scale international HIV preventative vaccine trials. Lancet. 1986;1:307–310.
    1. Scott LE, Galpin JS, Glencross DK. Multiple method comparison: statistical model using percentage similarity. Cytometry: Clinical Communication. 2003;54B:46–53.
    1. Azikiwe AN. Platelet count values in healthy Nigeria medical students in Jos. East Afr Med J. 1984;61:482–485.
    1. Gill GV, England A, Marshal C. Low platelet counts in Zambians. Trans R Soc Trop Med Hyg. 1979;73:111–112.
    1. Ezeilo GC. Non-genetic neutropenia in Africans. Lancet. 1972;2:1003–1004.
    1. Kasili EG, Cardwell CL, Taylor JR. Leucocyte counts on blood donors in Nairobi. East Afr Med J. 1969;46:676–679.
    1. Shaper AG, Lewis P. Genetic neutropenia in people of African origin. Lancet. 1971;2:1021–1023.
    1. Tugume SB, Piwowar EM, Lutalo T, Mugyenyi PN, Grant RM, et al. Hematological reference ranges among healthy Ugandans. Clin Diagn Lab Immunol. 1995;2:233–235.
    1. Beighton P, Solomon L, Soskolne CL, Sweet B, Robin G. Serum uric acid concentrations in an urbanized South African Negro population. Ann Rheum Dis. 1974;33:442–445.
    1. Koh ET, Chi MS, Lowenstein FW. Comparison of selected blood components by race, sex, and age. Am J Clin Nutr. 1980;33:1828–1835.
    1. Brickman AS, Nyby MD, Griffiths RF, von Hungen K, Tuck ML. Racial differences in platelet cytosolic calcium and calcitropic hormones in normotensive subjects. Am J Hypertens. 1993;6:46–51.
    1. Aboul-Hassan S, el-Shazly AM, Farag MK, Habib KS, Morsy TA. Epidemiological, clinical and laboratory studies on parasitic infections as a cause of fever of undetermined origin in Dakahlia Governorate, Egypt. J Egypt Soc Parasitol. 1997;27:47–57.
    1. Booth M, Vennervald BJ, Kenty L, Butterworth AE, Kariuki HC, et al. Micro-geographical variation in exposure to Schistosoma mansoni and malaria, and exacerbation of splenomegaly in Kenyan school-aged children. BMC Infect Dis. 2004;4:13.
    1. Bedu-Addo G, Bates I. Causes of massive tropical splenomegaly in Ghana. Lancet. 2002;360:449–454.
    1. Biggar RJ, Ortiz-Conde BA, Bagni RK, Bakaki PM, Wang CD, et al. Hepatitis C virus genotype 4 in Ugandan children and their mothers. Emerg Infect Dis. 2006;12:1440–1443.
    1. Tess BH, Levin A, Brubaker G, Shao J, Drummond JE, et al. Seroprevalence of hepatitis C virus in the general population of northwest Tanzania. Am J Trop Med Hyg. 2000;62:138–141.
    1. Seedat YK, Hackland DB, Mpontshane J. The prevalence of hypertension in rural Zulus. A preliminary study. S Afr Med J. 1981;60:7–10.
    1. van Rooyen JM, Huisman HW, Eloff FC, Laubscher PJ, Malan L, et al. Cardiovascular reactivity in Black South-African males of different age groups: the influence of urbanization. Ethn Dis. 2002;12:69–75.
    1. Kamali A, Quigley M, Nakiyingi J, Kinsman J, Kengeya-Kayondo J, et al. Syndromic management of sexually-transmitted infections and behaviour change interventions on transmission of HIV-1 in rural Uganda: a community randomised trial. Lancet. 2003;361:645–652.

Source: PubMed

3
구독하다